STOCK TITAN

Replimune (REPL) awards stock options and RSUs to director Astley-Sparke

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Replimune Group director Philip Astley-Sparke reported compensation-related equity awards. He received a stock option for 75,000 shares of common stock at an exercise price of 7.6100 per share, expiring on April 1, 2036. Twenty-five percent of this option vests on April 1, 2027, with the rest vesting in 36 approximately equal monthly installments.

He also received 50,000 shares of common stock issuable upon settlement of restricted stock units, with 25% vesting on May 15, 2027 and the remainder in three approximately equal annual installments through May 15, 2030, subject to continuous service. Following the grant, he directly holds 1,430,071 common shares. These are grants/awards, not open-market purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Astley-Sparke Philip
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 75,000 $0.00 --
Grant/Award Common Stock 50,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 75,000 shares (Direct); Common Stock — 1,430,071 shares (Direct)
Footnotes (1)
  1. Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer. 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.
Stock option grant size 75,000 shares Stock Option (right to buy) granted on April 1, 2026
Option exercise price 7.6100 per share Exercise price for 75,000-share stock option
Option expiration April 1, 2036 Expiration date of stock option grant
RSU grant size 50,000 shares Common stock issuable upon RSU settlement granted April 1, 2026
RSU initial vesting date May 15, 2027 25% of RSUs vest on this date
Shares after grant 1,430,071 shares Total common shares directly held after common stock grant
restricted stock units ("RSUs") financial
"Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price": "7.6100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date": "2036-04-01T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Astley-Sparke Philip

(Last)(First)(Middle)
C/O REPLIMUNE GROUP, INC.
500 UNICORN PARK DRIVE, SUITE 303

(Street)
WOBURN MASSACHUSETTS 01801

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Replimune Group, Inc. [ REPL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/01/2026A50,000(1)A$01,430,071D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$7.6104/01/2026A75,000 (2)04/01/2036Common Stock75,000$075,000D
Explanation of Responses:
1. Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer.
2. 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.
Remarks:
This Form 4 is being filed late due to inadvertent administrative error.
/s/ Shawn Glidden, attorney-in-fact04/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider equity awards did REPL director Philip Astley-Sparke report?

Philip Astley-Sparke reported receiving a stock option for 75,000 shares and 50,000 restricted stock units in Replimune Group. Both awards are compensation-related grants, with multi-year vesting schedules starting in 2027 and no open-market share purchases or sales disclosed.

How many Replimune (REPL) options were granted to Philip Astley-Sparke?

He was granted a stock option covering 75,000 shares of Replimune common stock. The option has an exercise price of 7.6100 per share, vests over roughly four years beginning April 1, 2027, and expires on April 1, 2036 if not exercised.

What are the vesting terms for Philip Astley-Sparke’s RSUs at Replimune (REPL)?

The 50,000 RSUs vest 25% on May 15, 2027, with the remaining units vesting in three approximately equal annual installments until May 15, 2030. Each vested restricted stock unit settles into one share of Replimune common stock, contingent on continued service.

How many Replimune (REPL) shares does Philip Astley-Sparke hold after these grants?

After the reported common stock grant, Philip Astley-Sparke directly holds 1,430,071 shares of Replimune common stock. This figure reflects his position immediately following the 50,000-share grant reported for April 1, 2026 on the Form 4.

Are the Replimune (REPL) Form 4 transactions open-market buys or sales?

The transactions are not open-market trades. They are grants or awards of a 75,000-share stock option and 50,000 restricted stock units, both issued at a transaction price of 0.0000 per share as part of compensation, with defined vesting schedules and no immediate cash purchase or sale.